EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

Fieke W Hoff iD, Roochi Trikha, Emma M Groarke iD, Bhavisha A Patel

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70302 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Fieke W Hoff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anemia, Macrocytic, DNA Methylation, Genetic Diseases, X-Linked, Ubiquitin-Activating Enzymes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms, reverse cytopenia, enable weaning of the corticosteroids and, in some cases, induce molecular remission. We systematically reviewed the literature to evaluate the experience with HMA in the management of VEXAS, following 2020 PRISMA guidelines across three databases. A total of 30 citations reporting 166 patients with genetically confirmed VEXAS syndrome treated with HMA were included. All but three patients were males (98%), and the median age was 71 years (range, 29–86). Inflammatory symptoms (96% of patients), constitutional symptoms (84%) and cytopenia (89%) were most frequently reported, and 81% had a concomitant diagnosis of myelodysplastic syndromes (MDS). Most mutations were substitutions of p.Met41 (81%). Overall inflammatory response was achieved in 59% of treated patients with most complete response (52%). Responses were documented in patients with and without concomitant MDS. Any haematological response was achieved in 74% of the patients, and eradication of the UBA1 clone (to a variant allele fraction of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, MacrocyticDNA MethylationGenetic Diseases, X-LinkedUbiquitin-Activating EnzymesAgedAged, 80 and overHumansMaleMiddle AgedMutationAdultMyelodysplastic SyndromesSkin Diseases, Genetic

Stichwörter der Autor:innen

UBA1VEXASazacitidinehypomethylating agent

Substanzen

UBA1 protein, humanUbiquitin-Activating Enzymes

Autor:innen und Institutionen

  • Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Haematology Department, King's College Hospital NHS Foundation Trust, London, UK.

ORCID-Profile: Fieke W Hoff, Emma M Groarke

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health

Zitieren

APA

Hoff, F. W., Trikha, R., Groarke, E. M., & Patel, B. A. (2026). Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review. British Journal of Haematology. https://doi.org/10.1111/bjh.70302

Vancouver

Hoff FW, Trikha R, Groarke EM, Patel BA. Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review. British Journal of Haematology. 2026. doi:10.1111/bjh.70302

BibTeX
@article{Hoff2026,
  author = {Hoff, Fieke W and Trikha, Roochi and Groarke, Emma M and Patel, Bhavisha A},
  title = {Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70302}
}
Kostenlos starten →